Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGHT: Prolonged Anticoagulation After PPCI in STEMI
NCT03664180Phase 4Completed
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bivalirudin, enoxaparin and heparin in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization at 30 days and Major bleeding at 30 days. Started Jan 2019; status: completed.
02
Drugs
bivalirudinenoxaparinheparin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03664180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664180.